SBIR/STTR Research Award

Novel Beetle Luciferases for Biomedical Development

Award identifier 4c0d4c3dfe82693dd6fd680fefe5fc8ae8df5e48e39ec3e50c642f27e70f0b42Awarding agency Department of Health and Human Services

Award amount

$737,548

Program and phase

SBIR · Phase II

Award year

1995

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
PROMEGA CORP.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Though radioactivity is widely used in bioassays due to its high sensitivity and convenience, safety and environmental concerns have accelerated efforts to eliminate its use. Recent procedures using luminescence have often surpassed conventional isotopic methods; among these the luminescence of firefly luciferase is the most efficient. Relevant biomedical applications include reporter gene technology, viral and cell tracer methods, non-isotopic immunoassays and other probe technologies, and clinical biomass/viability assays. Through fundamental research on the enzymatic mechanism of beetle luciferases, we have developed new chemistry which provides greater luminescence intensity with simpler reaction kinetics. To better understand the commercial potential of beetle luciferases and to develop specific enzymes suited for applications, we are currently examining the structure and function of several adult-form isozymes. This project is for extending our investigations to include a new class of isozymes derived from embryonic and juvenile developmental forms of elaterid beetles. These isozymes are spectrally unique, and taxonomic data reveals that they are evolutionarily divergent. Yet, due to inaccessibility, these enzymes have never been investigated biochemically. In Phase l, genes encoding these novel isozymes will be isolated to allow for enzymological and physical studies of the recombinant enzymes planned for Phase II.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.